A randomized Bayesian phase I-II dose optimization design for combination cancer therapies with progression-free survival end point
The proposed COMPACT design offers a novel and robust framework for combination cancer therapies with progression-free survival end point.
Authors
- Yingjie Qiu (ORCID: https://orcid.org/0009-0009-9429-2131)
- Mingyue Li (ORCID: https://orcid.org/0000-0001-7215-4103)
Institutions
- Southwestern Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- BMC Medical Research Methodology
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1186/s12874-025-02665-4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health